Interactive question and answer session - PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease.

27 August 2018 (13:55 - 14:00)

Organised by:

About the speaker

Professor Deepak Bhatt

Icahn School of Medicine at Mount Sinai, New York City (United States of America)

4 More presentations in this session

Presentation thumbnail

Chairman’s welcome and introduction: the mandate for improving residual cardiovascular disease risk reduction in patients with adversely elevated LDL-C

Professor D. Bhatt (New York City, US)

Presentation thumbnail

What do recent landmark, cardiovascular outcome trials evaluating PCSK9 inhibition in high risk patient populations teach us?

Professor P. Steg (Paris, FR)

Presentation thumbnail

Guidelines and the role of non-statin therapies for ASCVD reduction in high risk patients - Addressing statin intolerance and poor target LDL-C goal attainment

Professor J. Jukema (Leiden, NL)

Presentation thumbnail

Getting real world and “hands on” in patients with elevated LDL-C and high risk features for atherosclerotic cardiovascular disease — Case management sessions.

Professor D. Bhatt (New York City, US)

Access the full session

Session thumbnail

PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease

The Event

ESC Congress 2018

27 August 2018 13:55 CET

You may be interested in

Congress Session

PCSK9 inhibitors for acute coronary syndromes: the era of early implementation

30 August 2024

Congress Presentation

PCSK9 inhibitors and incidence of arrhythmias in clinical practice: a phase IV multicentric study

18 April 2023

Congress Presentation

2 September 2019

Congress Presentation

Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes

1 September 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources